Literature DB >> 35399693

An Autopsy Case of Metastatic Melanoma Originating from the Nasal Cavity That Was Treated With Nivolumab and Ipilimumab.

Yoshihiro Komohara1,2, Tomohiro Miyamura3, Azusa Miyashita3, Hikaru Shigeta1, Takenobu Nakagawa1, Satoshi Fukushima3.   

Abstract

Background: Recent developments in antibodies targeting checkpoint molecules have improved the overall survival of patients with melanoma. Case Report: A case of metastatic melanoma was treated with antibodies to cytotoxic T-lymphocyte-associated protein 4 and programmed cell death protein 1. Stable disease was achieved but the patient died from systemic metastasis 23 months after the diagnosis of melanoma. An autopsy was performed, and immunohistochemical analysis was carried out using primary melanoma (pre-treatment) and autopsy (post-treatment) samples. The down-regulation of human leukocyte antigen class I and II, melanin, and melanoma antigens was seen in the post-treatment tumor cells. Tumor-infiltrating lymphocyte numbers were significantly reduced in the post-treatment tumor microenvironment. Although programmed death ligand 1 expression was seen in the pre-treatment tumor tissues, it was not seen in the post-treatment tumor tissues.
Conclusion: A phenotypical change in the tumor cells was suggested to be associated with the resistance to immune checkpoint inhibitor therapy. Copyright 2021, International Institute of Anticancer Research.

Entities:  

Keywords:  Melanoma; autopsy; ipilimumab; nivolumab; resistance

Year:  2021        PMID: 35399693      PMCID: PMC8962771          DOI: 10.21873/cdp.10001

Source DB:  PubMed          Journal:  Cancer Diagn Progn        ISSN: 2732-7787


  13 in total

Review 1.  Classifying Cancers Based on T-cell Infiltration and PD-L1.

Authors:  Michele W L Teng; Shin Foong Ngiow; Antoni Ribas; Mark J Smyth
Journal:  Cancer Res       Date:  2015-06-01       Impact factor: 12.701

2.  Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean-Jacques Grob; Piotr Rutkowski; Christopher D Lao; C Lance Cowey; Dirk Schadendorf; John Wagstaff; Reinhard Dummer; Pier F Ferrucci; Michael Smylie; David Hogg; Andrew Hill; Ivan Márquez-Rodas; John Haanen; Massimo Guidoboni; Michele Maio; Patrick Schöffski; Matteo S Carlino; Céleste Lebbé; Grant McArthur; Paolo A Ascierto; Gregory A Daniels; Georgina V Long; Lars Bastholt; Jasmine I Rizzo; Agnes Balogh; Andriy Moshyk; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2019-09-28       Impact factor: 91.245

3.  Cancer Cell-Intrinsic Expression of MHC Class II Regulates the Immune Microenvironment and Response to Anti-PD-1 Therapy in Lung Adenocarcinoma.

Authors:  Amber M Johnson; Bonnie L Bullock; Alexander J Neuwelt; Joanna M Poczobutt; Rachael E Kaspar; Howard Y Li; Jeff W Kwak; Katharina Hopp; Mary C M Weiser-Evans; Lynn E Heasley; Erin L Schenk; Eric T Clambey; Raphael A Nemenoff
Journal:  J Immunol       Date:  2020-03-16       Impact factor: 5.422

4.  Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.

Authors:  Claudia Schweizer; Philipp Schubert; Sandra Rutzner; Markus Eckstein; Marlen Haderlein; Sebastian Lettmaier; Sabine Semrau; Antoniu-Oreste Gostian; Benjamin Frey; Udo S Gaipl; Jian-Guo Zhou; Rainer Fietkau; Markus Hecht
Journal:  Eur J Cancer       Date:  2020-10-09       Impact factor: 9.162

5.  Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort.

Authors:  Abdul Rafeh Naqash; Biagio Ricciuti; Dwight H Owen; Vaia Florou; Yukihiro Toi; Cynthia Cherry; Maida Hafiz; Andrea De Giglio; Mavish Muzaffar; Sandip H Patel; Shunichi Sugawara; Jarred Burkart; Wungki Park; Rita Chiari; Jun Sugisaka; Gregory A Otterson; Gilberto de Lima Lopes; Paul R Walker
Journal:  Cancer Immunol Immunother       Date:  2020-03-05       Impact factor: 6.968

6.  Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer.

Authors:  David Y Oh; Serena S Kwek; Siddharth S Raju; Tony Li; Elizabeth McCarthy; Eric Chow; Dvir Aran; Arielle Ilano; Chien-Chun Steven Pai; Chiara Rancan; Kathryn Allaire; Arun Burra; Yang Sun; Matthew H Spitzer; Serghei Mangul; Sima Porten; Maxwell V Meng; Terence W Friedlander; Chun Jimmie Ye; Lawrence Fong
Journal:  Cell       Date:  2020-06-03       Impact factor: 41.582

Review 7.  Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors.

Authors:  Satya Das; Douglas B Johnson
Journal:  J Immunother Cancer       Date:  2019-11-15       Impact factor: 13.751

8.  Myasthenic crisis and polymyositis induced by one dose of nivolumab.

Authors:  Toshihiro Kimura; Satoshi Fukushima; Azusa Miyashita; Jun Aoi; Masatoshi Jinnin; Takayuki Kosaka; Yukio Ando; Masakazu Matsukawa; Hiroyuki Inoue; Kazuma Kiyotani; Jae-Hyun Park; Yusuke Nakamura; Hironobu Ihn
Journal:  Cancer Sci       Date:  2016-07       Impact factor: 6.716

9.  Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma.

Authors:  Caroline Robert; Georgina V Long; Benjamin Brady; Caroline Dutriaux; Anna Maria Di Giacomo; Laurent Mortier; Piotr Rutkowski; Jessica C Hassel; Catriona M McNeil; Ewa Anna Kalinka; Céleste Lebbé; Julie Charles; Micaela M Hernberg; Kerry J Savage; Vanna Chiarion-Sileni; Catalin Mihalcioiu; Cornelia Mauch; Ana Arance; Francesco Cognetti; Lars Ny; Henrik Schmidt; Dirk Schadendorf; Helen Gogas; Jesús Zoco; Sandra Re; Paolo A Ascierto; Victoria Atkinson
Journal:  J Clin Oncol       Date:  2020-09-30       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.